4d Pharma Share Discussion Threads

[someuwin] 23/9/2019 08:14

Remember that 4D are already working with Merk & Co (NYSE:MRK - $200bn valuation) on collaboration with their blockbuster cancer immunotherapy drug, Keytruda which has sales of $1.67 billion last year.

[someuwin] 23/9/2019 08:07

So a potential treatment for Parkinson's then. as well as current programs for cancer, Asthma and gastrointestinal diseases.

Expect corporate action very soon imo. Joint Venture with one or more majors or outright takeover.

[someuwin] 23/9/2019 07:08

4D pharma plc

(the "Company" or "4D")

Publication of data on neurodegenerative disease programmes

4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper outlining the ability of MRx0005 and MRx0029 to modulate neuroinflammatory and neurodegenerative processes in vitro.

The paper 'In vitro characterisation of gut microbiota-derived bacterial strains with neuroprotective properties' (Ahmed et al.) is published in the journal Frontiers in Cellular Neuroscience.

Through screening a panel of gut bacterial strains using the Company's MicroRx® platform, 4D researchers have identified two single-strain Live Biotherapeutic candidates, MRx0005 (Parabacteroides distasonis) and MRx0029 (Megasphaera massiliensis), with potent effects on neuroinflammation and intrinsic antioxidant capacity. MRx0029 also displayed neuroprotective properties and induced a mature phenotype in undifferentiated neuronal cells. The team were able to associate many of the observed effects with specific short-chain fatty acids produced by the bacteria.

The Company has previously presented additional data demonstrating the efficacy of MRx0029 and MRx0005 in the MPTP model of Parkinson's disease.

Dr Alex Stevenson, 4D's Chief Scientific Officer, commented: "Neurodegenerative diseases, such as Parkinson's disease, are areas of high unmet need that have historically been challenging for the pharmaceutical industry. Single-strain Live Biotherapeutics present an opportunity as disease-modifying therapies to fundamentally change the way these patients are treated."

He added: "As we make good clinical progress with our lead programmes in cancer, asthma and gastrointestinal disease, our scientists continue to produce world-leading research to identify the next generation of Live Biotherapeutics."

Please find a copy of the paper here:

[k1ngkonggb] 20/9/2019 20:46

Ch1ck,

Try this but don't know much about him:

hxxps://www.marketscreener.com/business-leaders/Richard-Griffiths-05J8QH-E/biography/

Obviously the market liked it.

[ch1ck] 20/9/2019 20:38

What do we know about Richard the guy who bought a 4% stake Or is it steak ?

[ch1ck] 20/9/2019 20:37

King You really know how to party :-)

[k1ngkonggb] 20/9/2019 19:51

Finished my champers now on the wife beater juice!!!

[pugugly] 20/9/2019 17:59

Ch1ck - Take it you were buying ay 65-65.5p on the 18th - brave man - well done - Champage this weekend?

[ch1ck] 20/9/2019 15:50

I don't care. All I know is I'm up 30%

[pugugly] 20/9/2019 13:30

Richard Griffiths DOES NOT WALK ON WATER !! He appears to be losing a very large packet on Plant Health Care - To follow him blindly should carry a LARGE wealth loss warning in some cases - FACT - As I know to my cost.

[someuwin] 20/9/2019 12:33

Also, the appointment of Dr. Sandy Macrae as NED last month.

...Dr. Macrae currently serves as President and Chief Executive Officer of Sangamo Therapeutics, Inc. ("Sangamo"; NASDAQ: SGMO), a leading genomic medicine company active in developing cell and gene therapies across a range of rare and large indications. Since Dr. Macrae joined Sangamo in 2016, the company has grown to have seven active clinical programmes, established multiple partnerships with major pharma groups, and seen its market capitalisation increase from around $350 million to approximately $1.35 billion today.

...Now why would the top man at a $billion NASDAQ co take a NED role at 4D? Note: He has no directorships of any other companies.

Something big is brewing here - imo.

[someuwin] 20/9/2019 11:58

Yes - Richard Griffiths takes almost 4%.

Now I'm convinced something very positive is going on here!

[achillesheel] 20/9/2019 11:52

Looks as though Griffiths has been buying stock from i assume Woodford.

[ch1ck] 20/9/2019 09:44

I was looking at Oxford Bio (Oxb) today interesting stock with directors buying but it has been falling I need to see a strong reversal before I buy but interested

[someuwin] 20/9/2019 08:24

Agreed, IF they have funding sorted these will bounce strongly.

Something was certainly happening yesterday with over 6m shares traded.

I just don't know how to read this one at the moment - especially with Woodford's major holding.

[ch1ck] 20/9/2019 08:15

Strange move yesterday, it looked like lots of shares being sold but the price goes up 10% any thoughts?If funding is in place and the MM knows this price will rocket

[rjmahan] 19/9/2019 23:37

But remember, directors know this and bought lots of shares.

[pugugly] 19/9/2019 10:09

re 143 - Thanks for the reminder and with Woody tapped out of cash new funders - if any prepared to gamble - will require many lbs of flesh (imo) Watch and wait might well be the most appropriate policy.

[someuwin] 19/9/2019 09:49

Basically, they need to raise a lot of cash (£25m - £30m?) soon...

21 May 2019

"Financial summary

In the year to December 2018, our cash and cash equivalents and short-term deposits reduced from GBP50.0 million to GBP26.2 million, with a loss before tax of GBP28.4 million (compared with GBP24.0 million in the year to December 2017). Our claim for research and development tax credit was GBP4.7 million (compared with GBP3.5 million in the year to December 2017).

Our cash burn for the year was in line with expectation, reflecting the increased costs of taking existing and new clinical programmes forward and preparing for upcoming Phase I and II trials.

The Group continues to manage its cash deposits prudently and invests its funds across a number of financial institutions which have investment grade credit ratings. The Board has continued to operate a robust set of financial controls including rolling short-term and long-term forecasts to assist in the control and prioritisation of resources.

The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities into the fourth quarter of 2019. The Directors are continuing to explore sources of finance available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts. They have therefore prepared the financial statements on a going concern basis.

Because the additional finance is not committed at the date of approval of these financial statements, these circumstances represent an uncertainty as to the Group's ability to continue as a going concern.

Should the Group be unable to obtain further finance such that the going concern basis of preparation was no longer appropriate, adjustments would be required including to reduce the carrying value of assets to their recoverable amounts, and to provide for future liabilities that may arise."

[ch1ck] 17/9/2019 19:31

Looks like shares are being picked up on down days in the market

[ch1ck] 30/8/2019 11:28

Lion We now know where you stand and if you think two or three posts are excessive maybe you you should check out other threads.This is a discussion forum and and a bit of interest here would not go amiss

[k1ngkonggb] 29/8/2019 16:11

Nowt wrong with a little ramping.....this share could do with some injection!!! :)

[lionheart69uk1] 29/8/2019 15:52

No need for the daily ramping Chick or are you that desperate?

[ch1ck] 29/8/2019 15:38

This is a well respected player in this niche market which would make a great bolt on to a business such as Glaxo. Once the phase trials are completed this has the potential to multi bag from here. Directors have been picking up large amounts of stock at the low I can see a slow climb with out news

[k1ngkonggb] 29/8/2019 11:37

As a non Exec Director but he will add some very invaluable experience. He's YET to have any interest in shares but if that changes then I can see some little rockets appearing!!!